

RESTRICTED – COMMERCIAL Mr Ashwin Upasane CIPLA LIMITED (UNIT IX) UNIT IX PLOT NO. L-139 S-103 M-62 VERNA INDUSTRIAL ESTATE VERNA GOA IN-403 722 INDIA



#### MHRA

10 South Colonnade Canary Wharf London E14 4PU United Kingdom

gov.uk/mhra







# Medicines and Healthcare products Regulatory Agency

## CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER

#### Part 1

Issued following an inspection in accordance with Art. 111(5) of Directive 2001/83/EC.

The competent authority of the United Kingdom confirms the following:

The manufacturer

CIPLA LIMITED (UNIT IX)

Site address

**UNIT IX** 

PLOT NO. L-139

S-103 M-62

VERNA INDUSTRIAL ESTATE

VERNA GOA IN-403 722 INDIA

Has been inspected in connection with marketing authorisation(s) listing manufacturers located outside of the European Economic Area in accordance with Art.111(4) of Directive 2001/83/EC transposed in the following national legislation: The Human Medicines Regulations 2012 (SI 2012/1916).

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 19/08/2019, it is considered that it complies with the principles and guidelines of Good Manufacturing Practice laid down in Directive 2003/94/EC.

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field.

This certificate is only valid when presented with all pages and both parts 1 and 2.

The authenticity of this certificate may be verified in EudraGMDP. If it does not appear please contact the issuing authority.





#### Part 2

**Human Medicinal Products** 

## 1. MANUFACTURING OPERATIONS

#### 1.1 Sterile products

- 1.1.1 Aseptically prepared (processing operations for the following dosage forms)
  - 1.1.1.2 Lyophilisates
  - 1.1.1.4 Small volume liquids
- 1.1.2 Terminally sterilised (processing operations for the following dosage forms)
  - 1.1.2.3 Small volume liquids

## 1.2 Non-sterile products

Not Authorised

## 1.3 Biological medicinal products

Not Authorised

## 1.4 Other products or manufacturing activity

1.4.2 Sterilisation of active substances/excipients/finished product

1.4.2.1 Filtration

1.4.2.3 Moist heat

### 1.5 Packaging

1.5.2 Secondary packaging

## 1.6 Quality control testing

- 1.6.1 Microbiological: sterility
- 1.6.2 Microbiological: non-sterility
- 1.6.3 Chemical/physical

### 2. IMPORTATION OF MEDICINAL PRODUCTS

## 2.1 Quality control testing of imported medicinal products

Not Authorised

## 2.2 Batch certification of imported medicinal products

Not Authorised

## 2.3 Other importation activities

Not Authorised













## 3. MANUFACTURING OPERATIONS

- 3.1 Manufacture of Active Substance by Chemical Synthesis
  Not Authorised
- 3.2 Processing Activities of Active Substance from Natural Sources
  Not Authorised
- 3.3 Manufacture of Active Substance using Biological Processes
  Not Authorised
- 3.4 Manufacture of sterile active substance Not Authorised
- 3.5 General Finishing Steps
  Not Authorised
- 3.6 Quality Control Testing Not Authorised
- 4 Other Activities
  Not Authorised







# Any restrictions or clarifying remarks related to the scope of this certificate:

Sterile product manufacture approved on Lines 1 and 2. The company committed to the MHRA to improvements following this inspection and other regulatory agency findings, in particular for controls with respect to cross contamination.

1. Building(s)/Area(s)

N/A

2. Room(s)

N/A

3. Line(s) Equipment(s)

N/A

4. QC testing

N/A

5. Medicinal Product(s)/IMP(s)

N/A

Name of the authorised person of the Competent Authority of the United Kingdom

Dr A J Gray Head of Inspectorate inspectionplanning@mhra.gov.uk

Date: 17/08/2020

